.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): VeraSeal, human fibrin...
Among other functions, the NK cells (Natural Killers, a type of lymphocyte formi...
Scientists from Johns Hopkins Medicine and eight other institutions in the Unite...
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, D...
A former Pfizer-turned-GSK scientist reportedly told colleagues that Pfizer dela...
The FDA has approved Soleno Therapeutics' Vykat XR as the first treatment for in...
Human medicines European public assessment report (EPAR): Cresemba, isavuconazol...
Human medicines European public assessment report (EPAR): Febuxostat Krka, febux...
Human medicines European public assessment report (EPAR): INOmax, nitric oxide, ...
Hours after Jay Bhattacharya was confirmed as NIH director, the agency directed ...
Minutes of the COMP meeting 18-19 February 2025
Merck & Co.’s subcutaneous formulation of Keytruda has matched up to the origina...
The share acquisition is the latest twist in a dispute between Alcon and fellow ...
The biotech is slashing a third of its workforce and more than half of its execu...
As part of an ongoing expansion strategy around the globe, Chiesi announced this...
Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. The ...
The Health and Human Services Department is set to slash 10,000 jobs and streaml...
The biotech is slashing a third of its workforce and more than half of its execu...
HHS is set to cut 10,000 jobs and consolidate divisions — have you been affected...
Human medicines European public assessment report (EPAR): Reagila, cariprazine, ...
Human medicines European public assessment report (EPAR): Pluvicto, lutetium (17...
The Food and Drug Administration will be substantially impacted, with cuts plann...
Japan faces a growing "Drug Loss" issue, but regulatory reforms and the J-ENTRY ...
Human medicines European public assessment report (EPAR): Uplizna, inebilizumab,...